CD163 and cutaneous melanoma: Furthermore, high serum levels of soluble CD163 were found to be associated with worse clinical outcome in metastatic RCC [29]; its measurement during treatment with anti PD-1 therapy seems to play a predictive role of effectiveness in patients with advanced cutaneous melanoma [30].